Is the NHS Value Based Procurement programme designed for us?

30th April 2024

This welcome initiative presents a transformed procurement landscape for Peezy Midstream, the evidence-based device that is shown to significantly reduce retesting and false positives sent unnecessarily to the lab, whilst improving analysis, diagnosis and treatment for women’s urological and prenatal point of care screening.

Peezy Mistream is designed also to improve patient care, infection control, reduced antibiotic prescribing … and better financial health for our NHS.

On which note, it is encouraging to read that no longer will a race to the cheapest priced product be the basis of assessment of value, with some reference to environmental impact, business model and supply chain resilience. The coming new dawn will, for the first time in years, see patient experiences and outcomes at the heart of the process.

Products that improve those outcomes will be scored higher, even if their price is higher – something which is hardly surprising for better, innovative products – and there will also be score boosts for those products that reduce relapses and so remove steps from the patient pathway, saving clinical time and freeing up resources, and so reducing overall system costs.

Read the full story at MedTech Insights from Whitehouse Communications.